Enable Injections
- Company typePrivate
- Founded2010
- HeadquartersCincinnati, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Enable Injections firmographics
Firmographics- Name
- Enable Injections
- Legal name
- Enable Injections, Inc.
- Website
- https://enableinjections.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Enable Injections industry classification
Industry- Product category
- Wearable Drug Delivery Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Wearable Injectors & On-Body Delivery Systems (HLAHAIAE)
- akta.pro secondary industries
- Drug Delivery Connectivity, Sensors & Digital Add-Ons (Smart Caps/Companion Apps) (HLAHAIAM), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)
Keywords
Where Enable Injections is headquartered
LocationHeadquarters
- HQ city
- Cincinnati
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Enable Injections business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Device Manufacturing and Supply: Enable manufactures and supplies enFuse devices to pharmaceutical partners for clinical and commercial use. Partners pay transfer price for clinical and commercial supply of enFuse devices.
- Partnership Licensing and Milestones: Partners obtain exclusive licenses to use enFuse technology with specific therapeutics. Enable receives upfront technology access fees, potential R&D milestones, commercial milestones, product sales, and single digit royalties.
- Strategic Investment: Enable receives strategic investments from pharmaceutical partners (e.g., $30M from Sanofi in January 2026) to accelerate manufacturing capabilities and supply chain development.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Enable Injections product offering
Product offeringCore offering
Enable Injections develops and manufactures the enFuse wearable drug delivery platform, a hands-free, purely mechanical on-body injector that delivers large volumes (5-25 mL per device, up to 100 mL with four simultaneous devices) of pharmaceutical and biologic therapeutics subcutaneously. The company works with pharmaceutical and biotech partners under licensing and supply agreements, providing devices for clinical trials and commercial combination products.
Differentiator
Problem solved
Functional benefit
Brands
- enFuse: The enFuse wearable drug delivery platform designed to deliver large volumes of medications subcutaneously, featuring hands-free wearable technology for patient self-administration.
- EMPAVELI Injector
- ASPAVELI enFuse
- CirCLIQ
Products and services
- enFuse Wearable Drug Delivery Platform Hands-free, purely mechanical on-body injector for subcutaneous delivery of 5-25 mL of pharmaceuticals and biologics; four devices can be worn simultaneously for up to 100 mL. Designed for at-home or in-clinic self-administration. Supplied to pharmaceutical partners for combination product development and commercialization.
- EMPAVELI Injector First commercial enFuse-based combination product, FDA-approved for at-home self-administration of pegcetacoplan (Apellis) for PNH, C3G, and primary IC-MPGN. Sold by Apellis in the US.
- ASPAVELI enFuse On-Body Delivery System CE-certified enFuse-based combination product for subcutaneous administration of Aspaveli (pegcetacoplan) for patients 12 years and older with PNH, C3G, and primary IC-MPGN; distributed by Sobi across the European Union.
- CirCLIQ On-Body Injector (Sarclisa SC) enFuse-based on-body injector used to deliver Sanofi's Sarclisa (isatuximab) subcutaneous formulation for multiple myeloma; the first anticancer treatment approved in the EU for administration via a portable injector.
Quantifiable outcome
- 100% of surveyed patients preferred enFuse over infusion pump in randomized control trial (SCIg study)
- +4 more outcomes
Companies that use Enable Injections
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles1 record
Enable Injections technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Enable Injections partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- Aptar Digital HealthcoreAptar Digital Health named Enable's preferred digital health partner for enFuse On-Body Delivery System. Partnership delivers companion digital solution including treatment data recording, onboarding modules, injection guidance, patient-reported outcomes, and symptom tracking. Solution expected to launch H2 2026.
- IncytecoreIncyte obtained worldwide exclusive license to use enFuse technology with its mutCALR-targeted therapy (INCA033989) in essential thrombocythemia (ET) and myelofibrosis (MF). Enable receives upfront technology access fee, R&D milestones, commercial milestones, and transfer price for device supply.
- Sobi (Swedish Orphan Biovitrum)coreDevelopment and distribution agreement for enFuse Injector for subcutaneous delivery of Aspaveli (pegcetacoplan). Sobi distributes ASPAVELI enFuse in European territories. Regulatory approvals obtained in EU (CE Mark 2026), Saudi Arabia, Brazil, South Korea, Canada.
- Serina TherapeuticsminorPartnership to develop and commercialize SER-252 (POZ-apomorphine) in combination with enFuse for advanced Parkinson's disease. Serina obtains worldwide exclusive license; Enable receives upfront fees, milestones, royalties. Clinical trial planned for Q4 2025.
- Viridian TherapeuticsminorPartnership to support one of Viridian's preclinical programs using enFuse technology for subcutaneous drug delivery.
- Apellis PharmaceuticalscoreEMPAVELI Injector (enFuse-based) received FDA approval in 2023 for subcutaneous delivery of pegcetacoplan for paroxysmal nocturnal hemoglobinuria. First commercial enFuse combination product. Apellis commercializes EMPAVELI Injector in the US.
- Roche (Genentech)corePartnership to integrate Roche's proprietary molecules with Enable's enFuse wearable drug-delivery technology, enabling patients to self-administer high-volume subcutaneous injections at home. Partnership expanded in May 2024.
- UCBminorStrategic partnership for development of subcutaneous drug delivery solutions using enFuse technology.
- CSLminorStrategic partnership for development of subcutaneous drug delivery solutions using enFuse technology.
Scale indicators9 records
Recent moves7 records
Expansion highlights5 records
Enable Injections competitors and assessment
Company assessmentDirect peers
- West Pharmaceutical Services: West's Device and Containment Solutions unit offers on-body wearable injectors (SmartDose, ContraFLO, and other platforms) for large-volume SC delivery. Closest direct competitor to Enable's enFuse, partnering with multiple large pharma companies across the same therapeutic areas.
- Ypsomed: Swiss device manufacturer with YpsoDose, a 2-step wearable injector for 1–10 mL SC delivery and broader pen/injector platforms. Directly competes for the same large-volume SC partnership deals with pharma companies.
- Stevanato Group: Italian manufacturer offering the On-Body Delivery System (OBDS) for large-volume SC biologics, plus integrated vial and syringe solutions. Directly comparable on-body technology competing for similar pharma combination-product opportunities.
- SHL Medical: Developer of wearable injectors including the Molly and Maggie autoinjector/wearable platforms. Directly comparable large-volume wearable technology competing with enFuse for pharma partnership wins.
- Phillips-Medisize (Molex): Contract developer of drug-delivery devices including on-body wearable injectors for pharma partners. Overlaps with Enable in B2B combination-product development and large-volume SC delivery engineering services.
Broad incumbents
- Becton Dickinson (BD): BD's Pharmaceutical Systems unit offers the Libertas wearable on-body injector plus a broad prefilled syringe and device portfolio. Comparable via large-volume SC combination products; competes from a much larger medtech incumbent position.
- Eli Lilly (delivery platform): Lilly has invested heavily in internal and partnered wearable on-body injector development for large-volume biologics (e.g., insulin, GLP-1, oncology). Competes as a vertically integrated pharma developing or sourcing similar delivery technology.
Emerging players
- Gerresheimer: Primary packaging and drug-delivery device company expanding into on-body injectors and large-volume SC systems. Comparable as a newer entrant building a wearable delivery platform for pharma partners.
Others
- Aptar Pharma: Digital health and drug delivery partner whose Aptar Digital Health division is Enable's preferred digital companion partner. Adjacent/complementary ecosystem participant rather than direct competitor.
- Sanofi (internal delivery): Enable's largest strategic investor and Sarclisa SC partner via CirCLIQ. Sanofi also explores alternative internal and external delivery platforms, making it both a partner and a structural risk to Enable's pipeline concentration.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Enable Injections social profiles
Digital presenceEnable Injections financial estimates
Financial estimateRevenue estimate
Valuation estimate
Enable Injections leadership team
Management profileNumber of profiles
Profiles18 records
Enable Injections funding detail
Funding detailFunding overview
Funding rounds8 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Enable Injections M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Enable Injections
What does Enable Injections do?
Enable Injections develops and manufactures the enFuse wearable drug delivery platform, a hands-free, purely mechanical on-body injector that delivers large volumes (5-25 mL per device, up to 100 mL with four simultaneous devices) of pharmaceutical and biologic therapeutics subcutaneously. The company works with pharmaceutical and biotech partners under licensing and supply agreements, providing devices for clinical trials and commercial combination products.
Is Enable Injections a public or private company?
Enable Injections is a private company. It is classified as venture growth investor backed and is currently operating.
When was Enable Injections founded?
Enable Injections was founded in 2010. It employs 101 to 250 people.
Where is Enable Injections based?
Enable Injections is headquartered in Cincinnati, United States, in the North America region.
How does Enable Injections make money?
Three revenue lines are on record. Device Manufacturing and Supply is the primary driver. The others are partnership Licensing and Milestones and strategic Investment.
Who are Enable Injections's main competitors?
Direct peers on record are West Pharmaceutical Services, Ypsomed, Stevanato Group, SHL Medical and Phillips-Medisize (Molex). Broad incumbents are Becton Dickinson (BD) and Eli Lilly (delivery platform). Gerresheimer is listed as an emerging player. Others are Aptar Pharma and Sanofi (internal delivery).
Does Enable Injections have an API?
No public API is recorded for Enable Injections.
What industry is Enable Injections in?
Enable Injections's product category is Wearable Drug Delivery Devices. Its primary akta.pro industry code is HLAHAIAE, Wearable Injectors & On-Body Delivery Systems, with a secondary code of HLAHAIAM, Drug Delivery Connectivity, Sensors & Digital Add-Ons (Smart Caps/Companion Apps). Its NAICS code is 334510 and its SIC code is 3841.